Sage Therapeutics reports Q2 EPS ($1.88), consensus ($1.67)
Sage recently completed enrollment in the Phase 3 STATUS Trial, the first ever global, randomized, double-blind, placebo-controlled trial in super-refractory status epilepticus. Sage continues to expect to report top-line results from the STATUS Trial in Q3, following completion of all study follow-up periods and data analysis. Based on a positive activity signal observed in the Part A open-label portion of the Phase 2 program of SAGE-217 in Parkinson's disease, Sage recently initiated an open-label Part B study to evaluate SAGE-217 as an adjunctive treatment in approximately 10 tremor-predominant Parkinson's disease patients. Top-line results from the Part B study are expected in the second half of 2017. Sage expects that its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements, based on its current operating plan, into Q2 of 2018.